Agenus Inc. (NASDAQ:AGEN - Get Free Report) shares crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $2.95 and traded as high as $3.16. Agenus shares last traded at $3.04, with a volume of 475,810 shares trading hands.
Analysts Set New Price Targets
Several analysts have commented on the company. Robert W. Baird increased their target price on Agenus from $3.00 to $4.00 and gave the company a "neutral" rating in a research note on Tuesday. HC Wainwright reiterated a "neutral" rating on shares of Agenus in a research report on Tuesday. StockNews.com raised Agenus from a "sell" rating to a "hold" rating in a research note on Friday, March 21st. Finally, B. Riley reaffirmed a "buy" rating on shares of Agenus in a report on Monday, April 21st. Six investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $9.00.
Check Out Our Latest Stock Report on Agenus
Agenus Price Performance
The company has a market capitalization of $73.04 million, a PE ratio of -0.31 and a beta of 1.48. The company's fifty day moving average is $2.17 and its 200-day moving average is $2.91.
Agenus (NASDAQ:AGEN - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The biotechnology company reported ($1.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.61) by $0.58. The business had revenue of $24.07 million for the quarter, compared to analysts' expectations of $26.38 million. Equities research analysts forecast that Agenus Inc. will post -12.55 EPS for the current fiscal year.
Hedge Funds Weigh In On Agenus
Institutional investors and hedge funds have recently bought and sold shares of the company. Apollon Wealth Management LLC purchased a new position in Agenus in the fourth quarter worth $55,000. Bank of Montreal Can purchased a new stake in shares of Agenus during the fourth quarter valued at $69,000. Gilead Sciences Inc. purchased a new stake in shares of Agenus during the fourth quarter valued at $635,000. B. Riley Financial Inc. purchased a new stake in shares of Agenus during the fourth quarter valued at $2,074,000. Finally, Barclays PLC grew its holdings in shares of Agenus by 295.3% during the third quarter. Barclays PLC now owns 27,813 shares of the biotechnology company's stock valued at $152,000 after buying an additional 20,777 shares during the last quarter. 61.46% of the stock is owned by hedge funds and other institutional investors.
About Agenus
(
Get Free Report)
Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Recommended Stories
Before you consider Agenus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agenus wasn't on the list.
While Agenus currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
